Low Dose Naltrexone (LDN) is a new, safe, and cost effective method of medical treatment by mobilizing the natural defenses of one’s own immune system. Folsom Medical Pharmacy is able to compound LDN in various strengths. While normally given at a dose of 0.5mg to 4.5mg as an oral capsule, we can also formulate LDN into a transdermal cream or an oral suspension. We can compound LDN into a dosage form that is free of fillers, including gluten, dyes, lactose, sugars, and other additives. Vegetable capsules are also available at Folsom Medical Pharmacy for patients who would like to avoid gelatin-based capsules. LDN is only available through compounding pharmacies.
Learn more about LDN treating common conditions:
Iyer, Lakshminarayan M., A. Maxwell Burroughs, Swadha Anand, Robson F. De Souza, and L. Aravind. “Polyvalent Proteins, a Pervasive Theme in the Intergenomic Biological Conflicts of Bacteriophages and Conjugative Elements.” Journal of Bacteriology 199.15 (2017)
Younger, J. and Mackey, S. (2009). Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. Pain Med, 10(4), pp.663-672.
Younger, Jarred, Luke Parkitny, and David McLain. “The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.” Clinical Rheumatology. Springer London, 2014. Web. 21 July 2017.
Chopra, P. and Cooper, M. (2013). Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology, 8(3), pp.470-476.
“Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.” Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study – ScienceDirect.
Woeller, K. (2009). Autism – The Benefits of Low Dose Naltrexone. [Blog] DR. KURT WOELLER – BIOMEDICAL AUTISM INTERVENTION. Available at: http://drkurtwoeller.blogspot.com/2009/01/autism-benefits-of-low-dose-naltrexone.html [Accessed 4 Jan. 2016].
Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N. and Ernst, M. (1993). Naltrexone in Autistic Children: Behavioral Symptoms and Attentional Learning. Journal of the American Academy of Child & Adolescent Psychiatry, 32(6), pp.1283-129
Rahn, K., McLaughlin, P. and Zagon, I. (2011). Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Research, 1381, pp.243-253.
Gironi, M., Martinelli-Boneschi, F., Sacerdote, P., Solaro, C., Zaffaroni, M., Cavarretta, R., Moiola, L., Bucello, S., Radaelli, M., Pilato, V., Rodegher, M., Cursi, M., Franchi, S., Martinelli, V., Nemni, R., Comi, G. and Martino, G. (2008). A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 14(8), pp.1076-1083.
Cree, Bruce A. C., Elena Kornyeyeva, and Douglas S. Goodin. “Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis.” Annals of Neurology. Wiley Subscription Services, Inc., A Wiley Company, 19 Feb. 2010
Smith, Jill P., Douglas Field, Sandra Bingaman, Robert Evans, and David Mauger. “SAFETY AND TOLERABILITY OF LOW DOSE NALTREXONE THERAPY IN CHILDREN WITH MODERATE TO SEVERE CROHN’S DISEASE: A PILOT STUDY.” Journal of clinical gastroenterology. U.S. National Library of Medicine, Apr. 2013
Smith, Jill P., Sandra I. Bingaman, Francesca Ruggiero, David T. Mauger, Aparna Mukherjee, Christopher O. McGovern, and Ian S. Zagon. “Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial.” SpringerLink. Springer US, 08 Mar. 2011.
Segal, D., J. K. Macdonald, and N. Chande. “Low dose naltrexone for induction of remission in Crohn’s disease.” The Cochrane database of systematic reviews. U.S. National Library of Medicine, 21 Feb. 2014